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Pharmacological aspects
This paper updates the 1996 review of treatment
approaches published in the Am J Geriatr Psychiatry
(1996;4[suppl 1]:S51-S65 [see ref 33]) and a chapter
in A Guide to Treatments that Work (Nathan PE,
Gorman JM, eds), Oxford University Press, New
York, 1998 [see ref 54]:. The major focus is on psy-
chopharmacology, with attention also to the evi-
dence for the efficacy of psychotherapeutic and
somatic approaches.
he treatment of depression in elderly patients
can be differentiated into acute, continua-
tion, and maintenance phases.The treatment goals in
each phase vary.The primary goal of acute treatment
is to achieve symptom remission. Once a patient has
improved symptom-atically,continuation phase treat-
ment attempts to prevent relapse back into the same
episode. The goals of maintenance treatment involve
sustaining recovery and preventing recurrences.
Related treatment objectives include improving
longevity and quality of life, enhancing functional
capacity,and improving general medical health status.
These issues must be considered in selecting treat-
ments and evaluating their outcomes.
Older adults with depression require active treatment,
particularly when symptoms interfere with everyday
functioning. Research has generally confirmed that
standard treatment approaches with proven efficacy
in younger populations are likely to be successful
when extended to the elderly,and that old age in itself
should not be considered a contraindication to their
use. However, even though safe and effective treat-
ments are available, nihilistic attitudes on the part of
professionals and negative attitudes of the elderly
themselves about psychiatric treatment remain barri-
ers to treatment.
Coexisting factors that frequently accompany
advanced age—for example, comorbid medical and
neurological illness, substance abuse, dementia, and
cognitive impairment—are probably greater influ-
ences than age itself on the effectiveness of antide-
pressant treatments in elderly patients. Such comor-
bidities may interfere with the modes of action of
specific treatments. Conversely, effective treatment
can improve outcomes of medical treatments and
rehabilitation efforts for physical illness in the
elderly,and influence survival (ie,depression is a risk
factor for mortality).Finally,depression is a risk fac-
tor for medical illness, and can complicate its treat-
ment.Thus,there may be serious risks of not treating
depression in physically ill elders (Reynolds, this
issue, pp 95-99).
Much of the treatment of depression in the elderly
occurs within the primary medical health care con-
text,if it occurs at all.Moreover,family members,typ-
ically spouses or daughters, provide the bulk of care
for older patients with mental disorders, often expe-
riencing considerable stress in the process.
A high proportion of patients experiencing an
episode of major depression in late life will have had
at least one previous episode, or will have a subse-
quent recurrence. The literature pertaining to the
long-term prevention of a recurrence of depression
is discussed elsewhere in this volume (Reynolds,this
issue,pp 95-99).These studies indicate that the long-
term prevention of new episodes of disorder in
elderly patients can be best achieved by maintaining
patients on the same dosage of antidepressant med-
ication that was used to treat the acute episode,and
by maintaining psychotherapy. Current recommen-
dations are for treatment to be continued for at least
6 months after remission
1 (Agency for Health Care
Policy and Research [AHCPR],1993).Newer infor-
mation,however,suggests a longer treatment period
may be necessary (Reynolds, this issue, pp 95 -97).
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Over the years, the amount of data from randomized
clinical trials or controlled clinical observation of anti-
depressant agents in elderly patients has been rather
limited,although in recent years there has been a sig-
nificant increase. Trials in mixed-age adults include
very few patients over 60 years of age.Typical outpa-
tient clinical trials for depression in the “elderly”have
average ages of only about 65 years and allow patients
who are as young as 60 years to be enrolled.The bulk
of the patients participating in clinical trials restricted
to the elderly are between 60 and 69 years of age,with
very few over 75.
2 Consequently, clinical recommen-
dations for the use of antidepressant drugs in elderly
patients have been largely derived from experience
with young or middle-aged adults.
1,3 Furthermore, the
elderly patients who do enter research studies repre-
sent an atypical sample of the older population,in that
they are volunteers in generally good medical health,
thus making it difficult to generalize trial results to
those who typically are encountered in primary care.
A systematic review of clinical trials for late-life
depression,performed in 1991 concluded from over 30
randomized, placebo-controlled, double-blind clinical
trials that antidepressants are more effective than
placebo in the treatment of acute depression.
4Approx-
imately 60% of patients showed clinical improvement,
although many patients retained significant residual
symptomatology. In general, the available antidepres-
sants were considered to be equally effective in the
elderly.These clinical trials were only of 3 to 8 weeks
duration, assessing only acute response. The medica-
tions were largely tricyclic antidepressants (TCAs),
trazodone, and bupropion.
Utilization data
Over the last decade there has been a marked trans-
formation in the types of antidepressants used clini-
cally in the elderly.Ten years ago,TCAs were used most
commonly.Since the advent and marketing in the US of
fluoxetine in 1988, there has been a gradual increase
in the uses of selective serotonin reuptake inhibitors
(SSRIs) and diminished use of TCAs. In 1998, TCAs
accounted for 21% of use in patients 70 years of age or
older and SSRIs accounted for 56% (personal commu-
nication from Cathryn Clary MD,Pfizer,Inc).The other
unique and mixed-action medications such as tra-
zodone, venlafaxine, bupropion, nefazodone, and mir-
tazapine accounted for the rest, ranging from 6.4% to
3.5% in the order of mention.The three major SSRIs of
1998, fluoxetine, sertraline, and paroxetine, each
accounted for approximately 15% to 20% of uses
(citalopram was not marketed until the last month of
1998). Amitriptyline was the most commonly used
TCA, accounting for 8.5% of uses, and used twice as
commonly as nortriptyline (4.4%) or doxepin (3.5%).
These data are all the more remarkable when the effi-
cacy evidence base is considered, as it will be below.
Tricyclic antidepressants
Thus the most commonly used TCAs in the elderly are
the tertiary amines amitriptyline and doxepin, and the
secondary amine nortriptyline, together accounting for
80% of uses.Among the TCAs,the latter two have been
preferred by geriatric experts because they have rela-
tively more favorable side-effect profiles than amitripty-
line and imipramine,both of which should generally be
avoided in elderly patients.Desipramine is less sedating
and can be given during the day; nortriptyline causes
less orthostatic hypotension than amitriptyline or
imipramine.Indeed,it remains surprising that amitripty-
line is still commonly prescribed in the USA,apparently
in preference to nortriptyline or desipramine, and to
trazodone and several newer alternatives.
Nortriptyline has been the most frequently directly stud-
ied TCA in elderly patients, involving 300 or more
patients in 22 clinical trials.
2,4 It is the only antidepressant
to have been directly and extensively studied in very
elderly patients (>80 year olds).
2 Results with nor-
triptyline suggest that the range of plasma concentra-
tions needed for a therapeutic effect is the same in both
younger and older patients. However, despite treating
patients at plasma levels within a presumed therapeutic
“window” (between 50 and 150 ng/mL), significant
residual depressive symptoms have been noted in one
half of patients in the clinical trials, and specific dosage
recommendations cannot be derived from these stud-
ies.
5 Clinical practice suggests that effective daily doses
in the elderly range from 50 mg to 100 mg, but this
should be taken as a guide at best.
There is considerable evidence that clinical response to
antidepressant drug therapy depends not only on ade-
quate dose and—in the case of TCAs—blood levels of
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medication, but adequate length of treatment as well.
There is a general consensus that significant response
often occurs later in elderly patients than in younger
patients,often after 6 to 12 weeks of therapy.
Medication compliance with TCAs by elderly patients is
especially important and difficult to achieve.It has been
estimated that 70% of patients fail to take 25% to 50%
of their medication.
6 Lack of adherence to instructions
results in wide fluctuations in plasma levels, which has
been shown to be predictive of poor outcome.Thus,the
measurement of plasma blood levels in elderly patients
is even more important than in younger patients,both to
verify compliance and to confirm that therapeutic drug
concentrations have been reached while remaining
below toxic levels.
Antidepressant treatment in the 1990s
Many treatment recommendations emanate from the
1991 NIH Consensus Development Conference
7,8 and
from the 1993 AHCPR guidelines.
9 At that time, the
SSRI fluoxetine had been available for only a few years,
and sertraline and paroxetine had not yet been released.
Many clinicians favored these medications because of
the decreased likelihood of anticholinergic and cardio-
vascular side effects.Two other SSRIs have been intro-
duced in the USA since then, fluvoxamine in 1996, and
citalopram, at the end of 1998. (Fluvoxamine is indi-
cated only for obsessive compulsive disorders in the US,
although it is indicated for depression in other parts of
the world.) In addition, three non-SSRIs, all with com-
plex neurotransmitter actions, have recently been mar-
keted, nefazodone and venlafaxine, as well as a nora-
drenergic medication,mirtazapine.
Selective serotonin reuptake inhibitors
To date,there have been at least 20 published clinical tri-
als of the SSRIs marketed in the USA as treatments for
depressed elderly patients—nine studies of fluoxetine
(Prozac®),eight of paroxetine (Paxil®),and three mul-
ticenter trials of sertraline (Zoloft®),comprising nearly
2000 elderly patients. These randomized clinical trials
have generally compared the SSRIs with older, more
established medications (often with imipramine),rather
than with each other or with placebo. The only large-
scale placebo-controlled trial that has been published
rather surprisingly suggested somewhat lower than
expected efficacy rates for fluoxetine.
10 (Multicenter
placebo-controlled trials of paroxetine and sertraline
have been completed, but results have not been pub-
lished.) Over 5- to 12-week study lengths, the various
SSRIs (though directly compared in only one random-
ized clinical trial) have appeared not to be differentially
efficacious in treating older patients, but equivalent in
efficacy to TCAs.One comparative but nonrandomized
study, however, has suggested a lesser efficacy for flu-
oxetine as compared with nortriptyline in elderly inpa-
tients with severe depression.
11 Overall,when compared
with tricyclic antidepressants, the SSRIs are equivalent
in efficacy in the elderly, with about 60% of patients
responding to treatment,although SSRI-treated patients
generally experienced fewer side effects.
Table I provides an overview of selected randomized
clinical trials comparing fluoxetine with a number of dif-
ferent antidepressants in elderly patients.
10-21 The trials
generally show no marked differences between fluoxe-
tine and the comparator drugs in end-point Hamilton
Depression Rating Scale scores (HAM-D). In fluoxe-
tine-treated patients, mean HAM-D scores at the end
point generally ranged from about 10 to 16, indicating
that the elderly subjects were left with significant residual
depressive symptoms.However,the studies were gener-
ally too short in duration (5 to 7 weeks) to be conclusive
inasmuch as elderly patients may require 6 to 12 weeks
of therapy for a full therapeutic effect, and duration of
response was not known. For example, patients in the
12-week fluoxetine vs sertraline trials generally had low-
est HAM-D scores,regardless of the SSRI used.
Similar results have been observed in short-term parox-
etine trials in elderly patients (Table II).
18,19,22-28 As with
fluoxetine,trial duration tended to be 6 weeks,HAM-D
scores decreased considerably, but residual symptoms
of depression remained at the end of the randomized
clinical trials,and mean end-point HAM-D scores were
generally in the range of 8 to 12.
There are fewer studies with sertraline (Table III),
18-21,29,30
but the duration of treatment is longer,extending from
8 to 12 weeks,the sample size per study is larger,and the
relatively higher dosages in these trials,ranging from 50
to 150 mg, were also more realistic. Sertraline was as
effective as amitriptyline,nortriptyline,and fluoxetine in
these direct comparisons.
Citalopram,an SSRI that has been available in Europe for
the last decade, is commonly used in the elderly. There
have been,however,relatively few efficacy studies focused
115116
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Table I. Selected clinical trials of fluoxetine in elderly patients with major depression. 
*Dosages are expressed as medians or ranges; †Sample size may indicate either completers or number of patients analyzed; ‡Indicates
MADRS; AMI, amitriptyline; BUP, bupropion; CMI, clomipramine; DOX, doxepin; FX, fluoxetine; HAMENDPT, Hamilton Depression Rating
Scale end point; MADRS, Montgomery-Asberg Depression Rating Scale; MIA, mianserin; NA, not available; NT, nortriptyline; PLC,
placebo; PX, paroxetine; SR, sertraline; TRZ, trazodone.
Study Drugs* Sample† Age Duration Dropout HAM-DENDPT Outcome
(years) (weeks)
Altamura et al,
12 1989  FX 20 mg 14 68 5  14% 14 FX=AMI
AMI 75 mg 14 28% 10
inpatients
La Pia et al,
13 1992  FX 20 mg 20 72 6 5% 14 FX=MIA
MIA 40 mg 20 20% 16
outpatients
Falk et al,
14 1989  FX 48 mg 14 68 7 21% 10 FX >TRZ
TRZ 350 mg 13 69% 16
Fairweather et al,
15 1993  FX 20 mg 33 70 6 9% 5‡ MADRS, FX=AMI
AMI 75 mg 33 5‡ FX>AMI attention / 
reaction time
Feighner and Cohn,
16 1985  FX 60 mg 78 68 (estim) 6 47% 16 FX=DOX
DOX 125 mg 79 61% 17
outpatients
Tollefson et al,
10 1995  FX 20 mg 335 68 6 22% 14 FX>PLC, 42% vs 30%
PLC 336 19% 16 responder rate
medically ill
Giakas et al,
17 1993  FX 40 mg 11 70 8 9% NA FX>BUP, 27% vs 0%
BUP <450 mg 13 46% responder rate
medically ill
Roose et al,
11 1994  FX 22 73 4-6 18% 16 NT>FX, 67% vs 23%
(not randomized) NT 42 70 19% 7 responder rate better
unipolar depression
and heart disease
Schone and Ludwig,
18 1993  FX 20-40 mg 52 74 6 14% 23 FX=PX, 18% vs 38%
PX 20-30 mg 54 11% 20 responder rate, FX<PX 
outpatients for cognition
Newhouse and Richter,
20 1994; FX 20-40 mg 119 68 12 22% 11 FX=SR, FX<SR
Linden et al,
21 1995  SR 50-100 mg 117 17% 11 attention and memoryTreatment of depression in late life - Schneider Dialogues in Clinical Neuroscience - Vol 1 . No.2 . 1999
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on the elderly. One compared citalopram with amitripty-
line finding similar efficacy
31 and the other reported effi-
cacy for citalopram compared with placebo in elderly
depressed patients both with and without dementia.
32
When compared with TCAs in standard controlled trials,
the SSRIs are equivalent in efficacy in the elderly, with
about 60% of patients responding to treatment.Regard-
less of the antidepressant agent used,the mean HAM-D
scores decreased from about 30 to 20 after 6 weeks of
treatment,although the fluoxetine-treated patients expe-
rienced fewer side effects.
16 A similar comparative
response was observed evaluating paroxetine and dox-
epin.
23 With either compound, the mean HAM-D scores
decreased from about 25 to 12 after 6 weeks of treatment.
SSRIs may have advantages over TCAs in treating
elderly patients, however, because of a more tolerable
side-effect profile.
33,34 In particular,in clinical trials,they
do not cause orthostasis or cognitive impairment when
compared with the other treatment group.Based on clin-
ical experience, they appear to have fewer anticholin-
ergic and cardiovascular side effects (though nausea
tends to be a particular problem).
27 Notably,in random-
ized clinical trials, their tolerability has appeared to be
only marginally superior to that of TCAs. In general,
the SSRIs as prescribed in these clinical trials do not
appear to differ substantially among themselves in side
effects; but this depends in part on dose and interindi-
vidual differences in pharmacokinetics and sensitivities.
Another consideration is the generalizability of the clin-
ical trial experiences to ordinary patients in clinical prac-
tices.A pharmacoepidemiological study on antidepres-
sant use in nursing-home patients suggested that SSRI
use was associated with falling to an extent equivalent to
TCAs.
35 One explanation is that patients in the clinical
trials were younger and healthier than those “real-
world”patients in nursing homes.
Other antidepressants
Other antidepressants include bupropion, venlafaxine,
nefazodone,trazodone,mirtazapine,and tianeptine.They
have diverse mechanisms of action,and as a group there
is not a considerable amount of published data from
elderly populations.
Bupropion may be as effective as TCAs and SSRIs in
the treatment of major depression and it is commonly
recommended for the elderly,although there is limited
evidence to support its use. Of concern, in two recent
studies, one in primary care offices and the other in
depressed patients with concomitant medical illnesses,
patients tended to be somewhat more intolerant to
bupropion than either imipramine or fluoxetine.
17,36 In
one placebo-controlled trial in the elderly, although
bupropion was effective, it was no more so than
imipramine.
36 Older placebo-controlled trials showed
mixed results.
37,38 In younger patients, it may cause
seizures at high doses and should be given in divided
doses. Since clinical trials have excluded patients with
cardiovascular disorders,bupropion's apparent margin
of safety would not necessarily be applicable to elderly
patients with concomitant cardiovascular disease.
36
Venlafaxine inhibits the reuptake of both serotonin and
norepinephrine.It is underresearched in elderly patients
and its role for the treatment of depression in late life is
uncertain. In clinical trials performed for the Food and
Drug Administration's (FDA) registration purposes,
elderly patients comprised only 229 out of 2000 patients
who received venlafaxine and only a relatively small
number of these were administered the drug for more
than 1 year. Nevertheless, data from the small subset
receiving long-term treatment suggest that tolerability is
equivalent to that in younger patients. A trial of ven-
lafaxine could be considered in elderly patients who do
not adequately respond to other drug modalities. Ven-
lafaxine has a wide dosage range of 75 to 350 mg/day,
administered in divided doses twice or three times daily
As with SSRIs, headache, insomnia, and nausea are
among the more frequent side effects. Other relatively
common reactions include somnolence,dry mouth,dizzi-
ness,sweating,and nervousness.Venlafaxine has caused
sustained, dose-related increases in systolic blood pres-
sure and diastolic blood pressure,and heart rate (1.1 to
4.5 beats/min).
39,40Although its effects on blood pressure
are not likely to be of clinical importance in an other-
wise healthy depressed patient, blood pressure moni-
toring is needed in patients with preexisting cardiovas-
cular disease or in those receiving relatively high
dosages. Recently, a sustained-release preparation has
become available that may lessen some of these effects.
Nefazodone is another agent with little published clini-
cal research in the elderly population, although clinical
trials have been performed in the elderly,and it thus has
an undefined role in the treatment of late-life depres-Pharmacological aspects
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Table II. Selected randomized clinical trials of paroxetine in elderly patients.
Symbols and abbreviations: see Table I.
Study Drugs Sample‡ Age Duration Dropout HAM-DENDPT Outcome
(years) (weeks)
Schone and Ludwig,
18 1993  PX 20-30 mg 54 74 6 11% 20 PX=FX, 38% vs 18%
FX 20-40 mg 52 14% 23 responder rate, PX>FX
outpatients for cognition
Hutchinson et al,
22 1992  PX 30 mg 58 72 6 21% 6 PX=AMI, fewer side 
AMI 100 mg 32 34% 6 effects, 76% vs 86% 
outpatients responder rate
Dunner et al,
23 1992  PX 23 mg 136 68 6 33% 12 PX(>)DOX, fewer side
(2 studies combined) DOX 105 mg 135 29% 13 effects
outpatients
Guillibert et al,
24 1988  PX 30 mg 40 69 6 22% 8 PX=CMI, 65% vs 72% 
CMI 75 mg 39 31% 8 responder rate
Rouillon,
25 1991  PX 30 mg 44 >60 6-9 23% NA PX=CMI, 71% vs 65% at 
CMI 75 mg 43 32% NA wk 6, 80% at wk 9
inpatients
Pelicier and Schaeffer,
26 1993  PX 20 mg 41 71 5 29% 11 PX=CMI, MADRS scores 
CMI <60 mg 42 24% 13 87% vs 79% responder rate
Geretsegger et al,
19 1995  PX 23 mg 44 71 6 36% 10 PX=AMI 64% vs 58% 
AMI 110 mg 47 34% 12 responder rate
inpatients
Dorman et al,
28 1990  PX 30 mg 29 >65 6 17% 12 PX(>)MIA
MIA 60 mg 28 11% 16
outpatients
Roose et al,
27 1998  PX 20 mg 41 58 6 10% PX=NT 61% vs 55% 
NT 75 mg 40 35% responder rate, 18% had 
adverse cardiac events
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sion. It has a dosage range of 300 to 500 mg/day, which
is administered in divided doses, twice daily.Although
associated with dose-related cognitive and psychomotor
effects, the drug seems to be relatively well tolerated
and relatively safe in overdosage. Ideally, the pharma-
ceutical company will release results of their trials.
Mirtazapine, in a randomized, double-blind trial in
elderly depressed patients, was somewhat less effective
than amitriptyline,
41 but was somewhat more effective
than trazodone or placebo in another 6-week trial.
42 In
the latter study, both treatments were associated with a
higher frequency of somnolence and dry mouth as com-
pared with placebo.Trazodone also had higher frequen-
cies of dizziness and blurred vision than placebo.
42
Tianeptine is an enhancer of presynaptic serotonin
uptake and has been marketed in Europe over the last
decade.One randomized trial including 315 elderly out-
patients showed equal tolerability and efficacy to
mianserin.
43
Efficacy vs effectiveness
Although TCAs and SSRIs have similar efficacy in
elderly patients,the effectiveness of SSRIs is likely to be
somewhat better. Efficacy is the measure of a medica-
tion's expected action when given to a defined popula-
tion for a defined problem, regardless of other consid-
erations such as tolerability, side effects, or dropouts.
Effectiveness is efficacy plus a favorable outcome,with
fewer complications under conditions faced by the
community-based practitioners. This distinction is
important since a larger percentage of primary care
physicians than psychiatrists treat depression in the
elderly and there are noteworthy differences between
the two types of practice. Psychiatrists see more
patients who are able to self-pay for service. Their
patients are thus likely to be more highly motivated,
and are also more likely to receive psychotherapy.Also
psychiatrists may be expected to help a patient better
cope with side effects. By contrast, primary care physi-
cians are less likely to require return appointments or
follow up on the depression, and spend less time with
their patients.This differential pattern of patient care
can lead to a different pattern of prescribing and a dif-
ferential pattern of effectiveness.
44
A significant measure of effectiveness in clinical trials
is the dropout rate. Tables I to III provide an overview
of dropout rates in many trials of SSRIs versus TCAs
and other active/control medications.Dropout rates for
patients on SSRIs were generally one third to one half
that of groups of patients treated with TCAs, although
there are notable exceptions.
This finding is not surprising when one considers the
benefit/side-effect profile of the TCAs.For example,nor-
triptyline may be favored because of predictable phar-
macokinetics and a relative lack of orthostatic hypoten-
sion. However, important disadvantages it shares with
other members of the TCA class include persistent psy-
chomotor and cognitive changes, as well as anticholin-
ergic effects. These undesirable secondary actions may
contribute to a high variability in patient acceptance.
In addition, certain adverse effects of TCA therapy in
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Table III. Selected randomized clinical trials of sertraline in elderly patients.
Symbols and abbreviations: see Table I.
Study Drugs Sample Age Duration Dropout HAM-DENDPT Outcome
(years) (weeks)
Cohn et al,
29  1990 SR 116 mg* 161 70 8 49% 10 SR=AMI, 69% vs 62% 
AMI 88 mg 80 51% 11 responder rate
McEntee et al,
30 1995  SR 50-150 mg 104 68 12 6% 10 SR=NT, 83% vs 80% 
NT 25-100 mg 104 12% 11 responder rate SR>NT for 
attention and memory
Newhouse and Richter,
20 1994;  SR 50-100 mg 117 68 12 17% 11 SR=FX, SR>FX for
Linden et al,
21 1995  FX 20-40 mg 119 22% 11 attention and memorygeneral can be particularly hazardous in the elderly.
These include orthostatic hypotension,sedation,and car-
diac toxicity. It has been suggested that TCAs, such as
type II (quinidine-like) antiarrhythmics,may actually be
proarrhythmic in patients who have ischemic heart dis-
ease,with potentially fatal outcome.
45
The improved tolerability of SSRIs is based on fewer
anticholinergic effects,little or no influence on cognition
in recommended doses, and no cardiovascular adverse
effects such as orthostatic hypotension,proarrhythmia,or
increased heart rate.Common complaints linked to these
agents include nausea,diarrhea,insomnia,headache,agi-
tation,and anxiety.Based on available data,it is not pos-
sible to determine whether or not the elderly are more
sensitive than younger populations to these more fre-
quent side effects.
2 It should also be noted that SSRIs
are metabolized in the liver and inhibit the drug metab-
olizing enzyme cytochrome P-450,particularly isoenzyme
CYP2D6,but others as well.The difference among SSRIs
in this respect is probably of limited importance despite
their heterogeneous metabolism. But this discussion is
beyond the scope of this paper. It is widely acknowl-
edged that a serotonin syndrome (excitation tremor,
pyrexia) or a potentially fatal drug-drug interaction may
occur if SSRIs are combined with MAOIs or L-trypto-
phan,or other drugs that might raise serotonin levels.
Under its Evidence-Based Practice Program to guide
clinical practice, the AHCPR reviewed newer antide-
pressants. With regard to older adults, and consistent
with the above, dropouts overall and due to adverse
effects do not differ significantly between older and
newer antidepressants.
46 In mixed-aged adults (data from
older adults not being available), subjects discontinued
treatment at similar rates for newer and older antide-
pressants due to lack of efficacy,adverse effects,or other
reasons. However, about 4% fewer patients taking
SSRIs discontinued treatment due to adverse effects
compared with patients taking TCAs. Compared with
TCAs, SSRIs had higher rate differences (7% to 10%)
of diarrhea, nausea, and insomnia, and a slight increase
in headaches. TCAs had higher rate differences of dry
mouth (30%), constipation (12%), dizziness (11%),
blurred vision,and tremors (4%).Of particular concern
in the elderly, several uncommon (<1%), but serious,
adverse effects were associated with the SSRIs,including
bradycardia, bleeding, granulocytopenia, seizures,
hyponatremia, hepatotoxicity, serotonin syndrome,
extrapyramidal effects,and mania.
Psychosocial therapy
Psychosocial treatments have an essential role in the
treatment of late-life depression because of the broad
range of functional and social consequences of
depression in the elderly.Antidepressant treatments
or electroconvulsive therapy (ECT) alone do not
resolve many of the problems associated with geri-
atric depression,including lack of social support,med-
ical illnesses, and significant and continuing adverse
life events.Further,some patients strongly prefer non-
biologic interventions, while others are not suitable
candidates for biologic interventions because of side
effects,concomitant illnesses,or other circumstances.
There are at least 8 randomized controlled trials indi-
cating that psychosocial interventions are efficacious
in treating major depression in the elderly (Table
IV).
47-54 Other controlled studies demonstrate the use
of psychosocial approaches in elderly samples of
mixed depression subtypes,including mild depression
or depressive symptoms. The treatments studied
include cognitive-behavioral, brief psychodynamic,
interpersonal,reminiscence/life review,and psychoe-
ducational modalities.For extensive reviews,see other
sources.
55,56 (Reminiscence and life-review therapies,
relatively specific to the elderly,emphasize the recall
and recounting of past life experiences, sometimes
with reinterpretation of their meanings or reworking
of issues previously left unresolved.
57)
In general,efficacy appears comparable for cognitive-
behavioral therapy and brief psychodynamic treat-
ments,showing significantly reduced depression over
6 weeks,relative to a delayed-treatment control con-
dition. Interpersonal therapy has not been directly
compared with other psychosocial approaches, but
generally shows equivalent responses.
51
The evidence suggests that reminiscence therapy or
psychoeducational interventions show efficacy in
reducing depressive symptoms and dysphoric affect in
elders with subclinical (or possibly dysthymic) forms
of depression, but their efficacy in treating older
adults who already manifest clinically diagnosable
depression has not been adequately established.
Psychosocial treatments—generally variants of cogni-
tive-behavioral therapy
58 or interpersonal therapy
59—
with depressed older adults who had concomitant
medical illness or physical impairments, such as nurs-
ing-home residents, generally show some antidepres-
Pharmacological aspects
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sant efficacy,but often with limitations in the effect or
duration of the benefit.
In summary, various forms of psychotherapy (particu-
larly cognitive-behavioral, psychodynamic, and inter-
personal approaches) have demonstrated efficacy in
decreasing depression in older adults, and the various
psychotherapies studied have generally proven equiva-
lent in their effects.These findings have been supported
by a meta-analysis of 17 published studies of psychoso-
cial treatments for depressed elderly patients,including
cognitive, psychodynamic, reminiscence, and eclectic
approaches.
60 Overall,these treatments are reliably more
effective than no-treatment conditions in reducing
depression, the short-term effect size comparing favor-
ably with the effect sizes for psychosocial treatments
with adults of younger ages.There is no clear advantage,
however,for group versus individual therapy or for any
particular treatment approach. In general, the findings
regarding treatment outcomes are comparable to those
found in psychotherapy research with younger adults.
Table IV. Controlled clinical trials of psychosocial interventions with elderly patients with major depression.
*Approximate mean or median age; CBT, cognitive-behavioral therapy; IPT, interpersonal therapy.
Study Comparison Sample Age* Gender Duration Sessions Baseline
conditions size (years) (% female) (weeks) Hamilton
Arean et al,
47 1993  Problem-solving 75 66 75 12 12 24
Reminiscence
Waiting List Control
Beutler et al,
48 1987  CBT + pill placebo 56 71 55 20 20 21
CBT + alprazolam
Pill placebo
Alprazolam
Brand and Clingempeel,
49 1992 Behavioral  therapy 53 72 89 2 8 24
+ standard hospital program
Standard hospital program
Gallagher and Thompson,
50 1982 Behavioral 30 68 77 12 16 18
Cognitive 
Psychodynamic
Sloane et al, 
51 1985 IPT 24 64 53 16 16 26
Nortriptyline
Pill placebo
Steuer et al,
52 1984 CBT 33 66 79 36 46 20
Psychodynamic
Thompson et al,
53 1991 Behavioral 91 67 67 12-16 16-20 19
Cognitive
Psychodynamic
Waiting List Control
Thompson et al,
54 1991 CBT 102 67 67 12-16 16-20 19
Desipramine
CBT + desipramineLong-term maintenance approaches are discussed else-
where
61 and in this issue (Reynolds,pp 95-97).
Electroconvulsive therapy in the elderly
ECT remains the most effective treatment for severe
major depression,despite its controversy.It is used partic-
ularly for patients with severe depression, delusional
depression, hallucinations and other psychotic features,
severe psychomotor slowing,catatonic stupor,and marked
or persistent suicidality. ECT should also be considered
for moderately or severely depressed patients who have
not responded to adequate trials of medications or who
have suffered from intolerable medication side effects.
Remission rates of 80% have been achieved for
severely depressed patients in recent studies.
62 Unilat-
eral,nondominant hemisphere,stimulus-titration meth-
ods are effective, reduce adverse side effects such as
post-ECT confusion and cognitive impairment, and
tend to be used initially.
63,64 Absolute contraindications
for ECT are few, the most notable being increased
intracranial pressure. With appropriate precautions,
ECT can be safely administered to patients with con-
current medical illnesses. Conditions that increase risk
of complications with ECT are recent myocardial
infarction and severe hypertension.The most common
post-ECT problems for patients over age 85 years
appear to be delirium or confusion (32%), transient
hypertension (67%),and reversible cardiac ectopy dur-
ing treatment (18%).
65
Although acute remission or response rates are high,
patients successfully completing a course of ECT may be
at risk for relapse and should be placed on maintenance
antidepressant.Although controlled clinical trials have
not been completed, many clinicians believe that main-
tenance ECT can be an effective strategy for preventing
early relapse in patients who have been refractory to or
intolerant of medication.Maintenance ECT is generally
given as an outpatient procedure every month.
Conclusions: from 1991 to 1999
Despite many more clinical trials involving the use of
newer antidepressant compounds, there is far too little
research that addresses the fundamental issues of effec-
tiveness and practical application in a variety of clinical
settings.The effectiveness of SSRIs in primary practice is
likely to be better than that of the TCAs from the per-
spective of tolerability and frequency of visits.Although
prescribing data suggest that practitioners are convinced
about the effectiveness of newer agents, there are too
few clinical trials, however, that provide head-to-head
comparisons of the newer agents in elderly populations.
Only limited generalizations can be made from the clin-
ical trials' data,and treatment recommendations are still
based upon young or middle-aged adults or relatively
healthier (younger,ages 60 to 69) older outpatients who
do not reflect the heterogeneity of patients with late-
life depression (as exemplified by the AHCPR evalua-
tion of new antidepressants).The same can be said for
psychosocial treatments. Nevertheless, for the reasons
discussed above, SSRIs currently are generally consid-
ered antidepressants of first choice among the elderly,at
least over the short term.
Much more needs to be done to evaluate clinical and
real-world outcomes, not just rating scale end points.
There is a need for disease management protocols that
are based upon a solid foundation of research in late-
life depression.There is a dearth of practical inpatient
and outpatient guidelines and treatment recommenda-
tions that take into account the wide interpatient vari-
ation and concomitant medications,or contain clinically
meaningful definitions for depression and treatment
response. In conclusion, new approaches to clinical
research are needed.
The AHCPR guidelines, NIH Consensus Conference,
and NIH Update on treating “geriatric depression”
all  stress that the efficacy of the various treatments
for depression in the elderly is, by and large, equiva-
lent to that found in adults in general. Differences,
however, in dealing with the elderly involve the
recognition of depression, overcoming barriers to
care, and the particular practical problems discussed
above. For example, the consequences of unrecog-
nized and untreated depression in the elderly include
increased health services utilization, longer hospital
stays, poor treatment compliance, and increased mor-
bidity and mortality from medical illness and suicide.
The costs of treatment are relatively modest and can
be minimized by careful monitoring of the patient's
clinical status.
Other points to be made include: (i) major depressive
disorder in late life is a treatable illness; (ii) evidence
for the specific efficacy of medication is based on
randomized placebo-controlled trials; (iii) evidence
exists for the efficacy of psychotherapy alone as a
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treatment for less severely ill, nonpsychotic outpa-
tients, though this area remains understudied; (iv)
electroconvulsive therapy appears to be effective in
geriatric patients with severe or psychotic major
depressive; (v) evidence for or against the efficacy of
combined acute phase treatment with both psy-
chotherapy and medication is generally lacking in
geriatric patients, but combined therapy is clearly a
clinical advantage; and (vi) the utility of maintenance
phase medication is suggested by a few studies. ❏
Tratamiento de la depresion de sujetos
de edad avanzada
El presente artículo actualiza la revisión de 1996 sobre
los enfoques terapéuticos, publicada en el Am J Geri-
atr Psychiatry 1996;4 (suppl 1):S51-65 (ver referencia
33) y el capítulo de A Guide to Treatments that Work
(Nathan PF, Gorman JM, eds), Oxford University
Press, New York, 1998 (ver referencia 54). Se centra el
interés en la psicofarmacología, poniendo énfasis tam-
bién en las pruebas existentes de la eficacia de la psi-
coterapia y de los enfoques somáticos.
Traitement de la dépression du sujet âgé
Cet article est une mise à jour d’une revue des
approches thérapeutiques de la dépression du sujet âgé,
publiée en 1996 dans l’Am J Geriatr Psychiatry 1996;4
(suppl 1):S51-65 (voir référence 33) et dans le chapitre
d’un livre publié en 1998,consacré aux traitements effi-
caces (A Guide to Treatments that work. Nathan PE,
Gorman JM, eds, Oxford University Press, New York,
1998) (voir référence 54).L’accent est tout particulière-
ment mis sur la psychopharmacologie, mais l’attention
se porte également sur les données qui établissent l’effi-
cacité de la psychothérapie et de l’approche somatique.
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